How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access.
Generic semaglutide could become dramatically cheaper after 2026, potentially reaching millions with type 2 diabetes and obesity in lower-income countries at fraction of current cost.
This production-cost analysis estimates potential generic semaglutide pricing using cost-plus methods applied to Indian active pharmaceutical ingredient shipment data, projecting that injectable semaglutide could reach $28-140/person-year (a fraction of current list prices) following 2026 patent expiry in 12 countries. The analysis identifies 162 countries with no patent barriers potentially gaining access to generic semaglutide by end of 2026, representing 69% of global T2DM burden and 84% of clinical obesity, though injection device costs and secondary patents remain barriers to equitable uptake.
What the study was
- Study design
- economic_analysis
- Population
- Global type 2 diabetes and clinical obesity populations (162 countries modeled)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Obesity (Silver Spring)
Why it surfaced
Directly relevant to GLP-1/cardiometabolic watchlist; landmark policy analysis of semaglutide global access trajectory; published in Obesity (Silver Spring); timely with 2026 patent expiries underway; corrected from HIGH to STANDARD: score 7 with no HIGH-forcing flag.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.